Author Correction: Oncogene Ablation-Resistant Pancreatic Cancer Cells Depend on Mitochondrial Function

Why It Matters

Accurate figure labeling preserves the integrity of a high‑impact cancer study and ensures downstream research builds on reliable data.

Key Takeaways

• Fig. 4a sample labels corrected to “No. 3” and “No. 4”.
• Mislabeling does not change article’s text or conclusions.
• Original study linked mitochondrial function to KRas‑driven pancreatic cancer resistance.
• Correction issued by Nature on 8 April 2026.
• Researchers urged to reference updated figure in future work.

Pulse Analysis

Scientific journals routinely publish corrections to safeguard the accuracy of the scholarly record. In this case, Nature corrected a mislabeling in the immunoblot panels of Figure 4a, a key visual that demonstrated phosphorylated AMPK and downstream signaling in KRas‑positive pancreatic tumors. While the error involved swapping sample identifiers, the authors confirmed that the underlying data and statistical analyses remain unchanged, meaning the study’s central claim—that mitochondrial metabolism sustains oncogene‑ablation‑resistant cells—still stands. Such transparency reinforces trust among researchers who rely on these findings for experimental design and hypothesis generation.

The original 2014 article reshaped the field’s understanding of pancreatic ductal adenocarcinoma (PDAC) by highlighting a metabolic vulnerability. By showing that KRas‑mutant tumors depend on mitochondrial oxidative phosphorylation, the work opened avenues for targeting metabolic enzymes, such as AMPK and ACC, in combination with conventional therapies. This insight has spurred preclinical programs and early‑phase clinical trials exploring mitochondrial inhibitors, positioning metabolic reprogramming as a complementary strategy to overcome resistance in aggressive cancers.

For biotech investors and drug developers, the correction carries practical implications. Accurate figure annotations are essential when translating preclinical data into target validation pipelines. Companies building on the mitochondrial dependency paradigm must cite the revised figure to avoid propagation of minor errors that could complicate regulatory submissions or intellectual property claims. Moreover, the prompt correction underscores the importance of rigorous data verification in high‑stakes oncology research, a lesson that resonates across the broader biomedical innovation ecosystem.